Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lineage Cell Therapeutics, Inc.

< Previous 1 2 3 4 Next >
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Appointment of General Counsel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Joins Russell 3000® and Russell Microcap® Indexes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
OpRegen® Data Update to Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage’s OPC1 Cell Therapy for the Treatment of Spinal Cord Injury to Return to Clinical Testing
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Announces Kevin L. Cook to Join as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.